Health Care • Medical Specialities
$414.50 ▼ -3.06
(-0.73%)
MKT CAP: $50.14B • VOL: 888.0K
52W L $163 52W H $457
HUM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $129.66B | $117.76B | $106.37B |
| YoY Revenue Growth % | +10.1% | +10.7% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $2.70B | $2.56B | $4.01B |
| Operating Margin % | 2.1% | 2.2% | 3.8% |
| Net Income (GAAP) | $1.19B | $1.21B | $2.49B |
| EBITDA (Normalized) | $3.14B | $3.02B | $7.84B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $921.0M | $2.97B | $3.98B |
| Capital Expenditures (CapEx) | $546.0M | $575.0M | $4.79B |
| Free Cash Flow (FCF) | $375.0M | $2.39B | -$805.8M |
| FCF Margin % | 0.3% | 2.0% | -0.8% |
| Return on Invested Capital (ROIC %) | 8.3% | 8.0% | 4.1% |
| Cash & Short-Term Equivalents | $4.20B | $2.22B | — |
| Total Debt (Short + Long Term) | $12.37B | $11.14B | $29.87B |
| Total Stockholders' Equity | $17.66B | $16.38B | $61.27B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HUM.